Cost-efficacy comparison of biological therapies for patients with moderate to severe psoriasis in Japan

References

• Lebwohl M. Psoriasis. Lancet. 2003;361:1197–1204.
   PubMed Web of Science ®Google Scholar
• Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun. 2010;34:314–321.
   PubMed Web of Science ®Google Scholar
• Tsai TF, Wang TS, Hung ST, Tsai PI, Schenkel B, Zhang M, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci. 2011;63:40–46.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Takahashi I, Tsuji H, Ibe M, Kinouchi M, Hashimoto Y, et al. Analysis of psoriatic patients registered in Asahikawa Medical College Hospital from 1983 to 2007. J Dermatol. 2009;36:632–637.
   PubMedGoogle Scholar
• Kawada A, Tezuka T, Nakamizo Y, Kimura H, Nakagawa H, Ohkido M, et al. A survey of psoriasis patients in Japan from 1982 to 2001. J Dermatol Sci. 2003;31:59–64.
   PubMed Web of Science ®Google Scholar
• Zachariae R, Zachariae H, Blomqvist K, Davidsson S, Molin L, Mork C, et al. Epidemiology and health service research quality of life in 6497 Nordic patients with psoriasis. Br J Dermatol. 2002;146:1006–1016.
   PubMed Web of Science ®Google Scholar
• Saurat JH, Guerin A, Yu AP, Latremouille-Viau D, Wu EQ, Gupta SR, et al. High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice. Dermatol. 2010;220:128–137.
   PubMed Web of Science ®Google Scholar
• Beyer V, Wolverton SE. Recent trends in systemic psoriasis treatment costs. Arch Dermatol. 2010;146:46–54.
   PubMed Web of Science ®Google Scholar
• Nelson AA, Pearce DJ, Fleischer AB, Balkrishnan R, Feldman SR. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. J Am Acad Dermatol. 2008;58:125–135.
   PubMed Web of Science ®Google Scholar
• Schmitt-Rau K, Rosenbach T, Radtke MA, Augustin M. Cost-effectiveness of biological therapy in remission induction of moderate to severe plaque psoriasis. Dermatol. 2010;221:236–242.
   PubMed Web of Science ®Google Scholar
• Sizto S, Bansback N, Feldman SR, Willian MK, Anis AH. Economic evaluation of systemic therapies for moderate to severe psoriasis. Br J Dermatol. 2009;160:1264–1272.
   PubMed Web of Science ®Google Scholar
• Anis AH, Bansback N, Sizto S, Gupta SR, Willian MK, Feldman SR. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States. J Dermatolog Treat. 2011;22:65–74.
   PubMed Web of Science ®Google Scholar
• Martin S, Feldman SR, Augustin M, Szapary P, Schenkel B. Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis. J Dermatolog Treat. 2011;22:138–143.
   PubMed Web of Science ®Google Scholar
• Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, et al. Etanercept and efalizumab for the treatment of psoriasis : a systematic review. Health Technol Assess. 2006;10:1–233.
   PubMedGoogle Scholar
• Reich K, Burden AD, Eaton JN, Hawkins NS. Efficacy of biologics in the treatment of moderate to severe psoriasis. A network meta-analysis of randomised controlled trials. Br J Dermatol. 2011;166:179–188.
   PubMedGoogle Scholar
• Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: Part 1. Value Health. 2011;14:417–428.
   PubMed Web of Science ®Google Scholar
• Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR task force on indirect treatment comparisons good research practices-Part 2. Value Health. 2011;14:429–437.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Yeilding N, Szapary P, Wang U, Li S, Zhu Y, et al. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rational for dosing recommendations. J Am Acad Dermatol. 2010;63:571–579.
   PubMed Web of Science ®Google Scholar
• Asahina A, Nakagawa H, Etoh T, Ohtsuki M. Adalimumab M04-688 Study Group. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a phase II/III randomized controlled study. J Dermatol. 2010;37:299–310.
   PubMed Web of Science ®Google Scholar
• Torii H, Nakagawa H. Japanese Infliximab Study Investigators. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci. 2010;59:40–49.
   PubMed Web of Science ®Google Scholar
• Igarashi A, Kato T, Kato M, Song M, Nakagawa H. Japanese Ustekinumab Study Group. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol. 2012;39:242–252.
   PubMed Web of Science ®Google Scholar
• Ministry of Health, Labour and Welfare, National Nutrition Survey. 2008. Available from http://www.mhlw.go.jp/bunya/kenkou/eiyou/dl/h20-houkoku-03.pdf. cited 5 January 2011.
   Google Scholar
• Sterry W, Ortonne JP, Kirkham B, Brocq O, Robertson D, Pedersen RD, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomized double blind multicentre trial. BMJ. 2010;340:C147.
   PubMed Web of Science ®Google Scholar
• Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106–115.
   PubMed Web of Science ®Google Scholar
• Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, et al. Efficady and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158:558–566.
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366:1367–1374.
   PubMed Web of Science ®Google Scholar
• Pearce DJ, Singh S, Balkrishnan R, Kulkarni A, Fleischer AB, Feldman SR. The negative impact of psoriasis on the workplace. J Dermatolog Treat. 2006;17:24–28.
   PubMed Web of Science ®Google Scholar
• Reich K, Schenkel B, Zhao N, Szapary P, Augustin M, Bourcier M, et al. Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2. J Dermatolog Treat. 2011;22:337–347.
   PubMed Web of Science ®Google Scholar